Fig. 2
From: Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine
Schema for group determination. All individuals will be assessed for dengue immunity by plaque reduction neutralization assays. Individuals will be considered immune if they have ≥ 70% reduction in infectious plaques at a 1:40 dilution. Those with monotypic immunity to DENV1, DENV2, or DENV4 (heterotypic to vaccine) and those with immunity to ≥ 2 serotypes, which can include DENV3 (polytypic), will be eligible. Individuals who do not meet the immunity threshold must have < 50% reduction in infectious plaques at 1:10 dilution against all serotypes to be included in the DENV seronegative group. Potential exposure to other flaviviruses as suggested by travel and/or vaccine history will trigger confirmatory antibody testing for the virus of interest. All seronegative individuals must also be flavivirus naïve.